Several patients have been dosed in the phase 3b ECLIPSE PV trial (NCT05481151), which is evaluating an accelerated dosing schedule of ropeginterferon alfa-2b-njft (Besremi) using a prefilled syringe for the treatment of patients with polycythemia vera (PV).
“This therapy represents an important addition to the treatment arsenal for PV in the U.S., and clinical data support its use across a broad range of patients regardless of their treatment history”.
“We are very proud to bring this to our community at University of Tennessee, Memphis (RegionalOne Health).” If you have any patients that would qualify please send an email to study coordinator: sgong@uthsc.edu”